Abbott Receives FDA Emergency Use Authorization for Breakthrough COVID-19 Tests

Beaufort extends its congratulations to Abbott for receiving successful FDA Emergency Use Authorization (EUA) of its BinaxNOW COVID-19 Ag Card Test and Rapid Antigen Self Test.

Abbott’s work at the early stages of the COVID-19 pandemic was instrumental in providing both healthcare providers and individuals with the critical tools needed to quickly identify infected populations and help contain further spread of the virus.

Beaufort’s Clinical Operations team provided extensive clinical monitoring services for Abbott’s EUA submission. We are proud of our partnership with Abbott as they continue to be the largest provider of rapid antigen tests in the United States.

Learn more about our full scope of Clinical Trial Services and how our team can support your medical innovation.

Read Press Releases from Abbott:

ABBOTT’S BINAXNOW™ RAPID ANTIGEN SELF TEST RECEIVES FDA EMERGENCY USE AUTHORIZATION FOR ASYMPTOMATIC, OVER-THE-COUNTER, NON-PRESCRIPTION, MULTI-TEST USE

ABBOTT’S FAST, $5, 15-MINUTE, EASY-TO-USE COVID-19 ANTIGEN TEST RECEIVES FDA EMERGENCY USE AUTHORIZATION; MOBILE APP DISPLAYS TEST RESULTS TO HELP OUR RETURN TO DAILY LIFE; RAMPING PRODUCTION TO 50 MILLION TESTS A MONTH

View all news & insights